Researchers at the University of Rochester will be using mHealth wearables to gather continuous, real-time data on how people living with Parkinson’s and Huntington’s Disease go through each day.

The New York university is partnering with MC10, a Lexington, MA-based developer of the digital health wearable Biostamp nPoint, to study the progressive effects of Central Nervous System diseases, particularly those involving movement disorders.

“Movement disorders such as Huntington’s and Parkinson’s disease represent a therapeutic area that lacks objective, quantitative understanding of disease progression, and therapeutic efficacy,” Dr. Arthur Combs, MD, MC10’s Chief Medical Officer, said in a press release.

“Wearable sensors, like those from MC10, have the potential to provide us such data that we can use to determine whether new therapies are efficacious.”

In 2017, the two used the BioStampRC – an earlier version of MC10’s wearable technology – in a study assessing motor symptoms in people living with Parkinson’s and Huntington’s Disease.

The university is now working with researchers at MIT, the University of Michigan Udall Center, Intel and MC10 “To develop and evaluate several remote monitoring and wearable technologies that will help researchers more precisely understand how Parkinson’s disease affects individuals beyond what is observed when patients visit the clinic, but also in their homes and daily lives.”

MC10 has long been one of the leaders in the mHealth wearables space.